Modification of an Amidolytic Heparin Assay to Express Protein-Bound Heparin and to Correct for the Effect of Antithrombin III Concentration

Summary

A modification of an anti-Xa assay for plasma heparin has been devised using a low molecular weight dextran sulfate that competitively binds protein heparin neutralizers and displaces masked heparin. The addition of 0.12 mg dextran sulfate per ml of plasma permits heparin, neutralized by the products of platelet aggregation, to recover full functional activity against Xa. The assay will permit a more accurate assessment of both exogenous plasma heparin and endogenous liepaiin-like activity in blood samples collected with varying techniques. A further modification is proposed employing polybrene to neutralize the plasma heparin-like material providing a concurrent control for each sample that increases accuracy by eliminating the effect of varying AT-III levels which have anti-Xa activity.

Keywords

Heparin - Antithrombin III - Dextran sulfate - Polybrene

• References

• 1 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
• 2 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 [PF 4] on assays of plasma heparin. Brit J Haemotol 1984; 57: 585-596
• 3 van Putten J, van de Ruit M, Beunis M, Hemker HC. Heparin neutralization during collection and processing of blood inhibited by Pyridoxal 5’-phosphate. Haem 1984; 14: 253-261
• 4 Contant G, Gouault-Heilman M, Martinoli JL. Heparin inactivation during blood storage. Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole. C.T.A.D. Mixture. Thromb Res 1983; 31: 365-374
• 5 Dawes J, Pepper DS. A sensitive competitive binding assay for exogenous and endogenous heparins. Thromb Res 1982; 27: 387-396
• 6 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 7 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor 4. J Biol Chem 1976; 251: 4273-4282
• 8 Lasser EC, Simon RA, Lyon SG, Hamblin AE, Stein R. Heparinlike anticoagulants in asthma. In press
• 9 Odegard OR, Fagerhol MK, Lie M. Heparin cofactor activity and antithrombin III concentration in plasma related to age and sex. Scand J Haematol 1976; 17: 258-262
• 10 Thaler E. Pathogenese und klinische Bedeutung des erworbenen Antithrombin-III-Mangels in der inneren Medizin. Wien Klin Wochenschr 1981; 93: 563-572
• 11 Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab 1979; 49: 719-725
• 12 McKay EJ, Laurell CB. The interaction of heparin with plasma proteins. J Lab Clin Med 1980; 95: 69-80
• 13 Lindahl U, Hook M. Glycosaminoglycans and their binding to biological macromolecules. Ann Rev Biochem 1978; 47: 385-417
• 14 Marciniak E. Binding of heparin in vitro and in vivo to plasma proteins. J Lab Clin Med 1974; 84: 344-356
• 15 Vannucchi S, Ruggiero M, Chiarugi V. Complexing of heparin with phosphatidylcholine. A possible supramolecular assembly of plasma heparin. Biochem J 1985; 227: 57-65
• 16 Khoory N, Nesheim ME, Bowie E JW, Mann KG. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest 1980; 65: 666-674
• 17 Palmer RN, Rick ME, Rick PD, Zeller JA, Gralnick HR. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 1984; 310: 1696-1699
• 18 Bussel JB, Steinherz PG, Miller DR, Hilgartner MW. A heparinlike anticoagulant in an eight-month old boy with acute monoblastic leukemia. Amer J Hematol 1982; 16: 83-90
• 19 Bick RL, Ross ES. Clinical use of intrapulmonary heparin. Sem Thromb Haemostasis 1985; 11: 213-217